IP Verse

Enhancing Anti-Cancer Activity Of Immunomodulatory Fc Fusion Proteins - EP2925350

The patent EP2925350 was granted to Bristol Myers Squibb on Jan 30, 2019. The application was originally filed on Dec 3, 2013 under application number EP13811698A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2925350

BRISTOL MYERS SQUIBB
Application Number
EP13811698A
Filing Date
Dec 3, 2013
Status
Opposition Rejected
Sep 17, 2021
Grant Date
Jan 30, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PLOUGMANN VINGTOFTOct 29, 2019-ADMISSIBLE

Patent Citations (43) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP1176195
DESCRIPTIONJP2008278814
DESCRIPTIONUS2004110704
DESCRIPTIONUS2012276086
DESCRIPTIONUS2013142783
DESCRIPTIONUS5977318
DESCRIPTIONUS6682736
DESCRIPTIONUS6803039
DESCRIPTIONUS6984720
DESCRIPTIONUS7030225
DESCRIPTIONUS7605238
DESCRIPTIONUS7722872
DESCRIPTIONUS7932358
DESCRIPTIONWO0243478
DESCRIPTIONWO03035835
DESCRIPTIONWO03106498
DESCRIPTIONWO2006089231
DESCRIPTIONWO2006105021
DESCRIPTIONWO2006121168
DESCRIPTIONWO2007062245
DESCRIPTIONWO2009079335
DESCRIPTIONWO2009101611
DESCRIPTIONWO2010096418
DESCRIPTIONWO2011028683
DESCRIPTIONWO2012027328
DESCRIPTIONWO2013008171
DESCRIPTIONWO2013028231
DESCRIPTIONWO2013038191
DESCRIPTIONWO9512673
DESCRIPTIONWO9942585
DESCRIPTIONWO9954342
INTERNATIONAL-SEARCH-REPORTWO2007048077
INTERNATIONAL-SEARCH-REPORTWO2007133822
INTERNATIONAL-SEARCH-REPORTWO2008137915
OPPOSITIONUS2007248595
OPPOSITIONUS6984720
OPPOSITIONWO2004063351
OPPOSITIONWO2005070963
OPPOSITIONWO2007048077
OPPOSITIONWO2007133822
OPPOSITIONWO2008137915
OPPOSITIONWO2012120500
OPPOSITIONWO2014089113

Non-Patent Literature (NPL) Citations (5) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "Iplimumab heralds new era of immune modulatory agents in cancer", EJC News, (20110700), vol. 47, no. 7-
OPPOSITION- Strohl, Et Al, "Mammalian cell lines", Therapeutic antibody engineering, Current and future advances driving the strongest growth area in the pharmaceutical industry, Woodhead Publishing Limited, (20120101), page 426, XP055663164-
OPPOSITION- Hyo Jin Park, Kusnadi Anthony, Lee Eun-Jung, Kim Won Woo, Cho Byoung Chul, Lee Ik Jae, Seong Jinsil, Ha Sang-Jun, "Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors", CELLULAR IMMUNOLOGY., ACADEMIC PRESS, SAN DIEGO, CA., US, US, (20120701), vol. 278, no. 1-2, doi:10.1016/j.cellimm.2012.07.001, ISSN 0008-8749, pages 76 - 83, XP055463616
OPPOSITION- R. Upton, Et Al, "Orthogonal Assessment of Biotherapeutic Glycosylation: A Case Study Correlating N-Glycan Core Afucosylation of Herceptin with Mechanism of Action", Analytical Chemistry, (20160913), vol. 88, pages 10259 - 10265, XP055663175
OPPOSITION- Natsume A, Niwa R, Satoh M., "Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC.", Drug Design, Development and Therapy, Dove Medical Press Ltd., United Kingdom, United Kingdom, (20090921), vol. 3, doi:10.2147/DDDT.S4378, ISSN 1177-8881, pages 7 - 16, XP002727883

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents